Cytoo

Pauline Poydenot

Joris Michaud

Eve Duchemin-Pelletier

Luc Selig

Mélanie Flaender

Yoran Margaron

Mathieu Fernandes

Sebastien Degot

Amelie Argento-Pucciarelli

Sébastien Degot

Amélie Argento-Pucciarelli

The present invention relates to ALK5 inhibitors and their uses as skeletal muscle hypertrophy inducers as well as to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting in loss of skeletal muscle tissue and/or muscle weakness. It further relates to the non-therapeutic use of such compounds to increase muscle mass, muscle strength and/or muscle performance in a subject.

ALK5 inhibitors as skeletal muscle hypertrophy inducers

The present invention relates to LSD1 inhibitors and their uses as skeletal muscle hypertrophy inducers as well as to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting in loss of skeletal muscle tissue and/or muscle weakness. It further relates to the non-therapeutic use of such compounds to increase muscle mass, muscle strength and/or muscle performance in a subject.

LSD1 inhibitors as skeletal muscle hypertrophy inducers

The invention relates to a method for high throughput screening compounds by using a plurality of automated cell based assays assessing skeletal muscle cells contractility, morphology, and metabolism, in order to predict the efficacy of said compound on a panel of applications linked with muscle physiological and pathophysiological processes, comprising: (i) providing an in vitro culture of myotubes, wherein the in vitro myotubes culture is obtained by the following method: providing a cell culture device allowing the culture of myoblasts or myotubes, depositing said cells from a human donor or human group of donors, in good health or affected by a muscle related disorder, from primary cells, a cell line, an isogenic cell line or differentiated stem cells recapitulating a muscle disorder, on said culture device by using a method allowing the spatial control of cell culture, culturing said cells during a determined incubation time so as to promote a spatially controlled myotube culture; (ii) adding at least one compound to said culture; (iii) after a determined incubation time of the myotubes with said compound, carrying out structural and/or functional readouts of the myotubes to determine the effect of said compound on the myotubes; and (iv) based on said determined effect, predicting the ability of said compound to improve or alter healthy muscle features, or to treat, rescue, or cure muscle disorders, said features or said disorders being linked with muscle contraction, muscle morphology or muscle metabolism.

High throughput and functional screening method for muscle related disorders and biological processes

Growing community of inventors

Saint Martin d'Heres, France

Pauline Poydenot